Abstract
BAY g 5421* delays starch as well as sucrose digestion in the small intestine by inhibiting glucosidases involved in the hydrolysis of oligosaccharides. As a consequence in loading tests with both carbohydrates the blood glucose and serum insulin increments are reduced in animals and in man. The ED 50 is approximately 0.5–3 mg BAY g 5421/kg per os.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Puls, W., Keup, U., Krause, H.P., Thomas, G. (1978). Pharmacological Characterization of Bay G 5421, A Glucosidase Inhibitor for the Treatment of Carbohydrate-Dependent Metabolic Disorders. In: Deutsche Pharmakologische Gesellschaft. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-39532-5_28
Download citation
DOI: https://doi.org/10.1007/978-3-662-39532-5_28
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-38666-8
Online ISBN: 978-3-662-39532-5
eBook Packages: Springer Book Archive